Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while losing weight, offering a potential solution to one of the key problems that’s emerged with popular obesity shots.

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination therapy might change that.

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.